Otsuka is committed to developing and launching products for better patient outcomes

Otsuka Pharmaceutical Group (Otsuka) develops drugs and treatments by understanding patients’ and doctors’ unmet medical needs and taking the time to explore the full potential of a compound. ABILIFY^® (aripiprazole)¹ was in development 22 years prior to commercialization and today is used by over 3 million patients.

Otsuka is committed to the “greater good” as demonstrated by the investments made to develop compounds in therapeutic areas that may not yield significant financial results. Examples include research investments in tuberculosis, which affects millions of patients in Africa and Asia, and the development of a compound for hyponatremia and polycystic kidney disease (PKD). Both hyponatremia and PKD have a small prevalence and might otherwise be ignored. The history of Otsuka’s development activities demonstrates its commitment to a long-term approach.
 

Otsuka is committed to pioneering innovative treatments to serve a wide spectrum of therapeutic areas. Otsuka is currently developing new treatments and indications focusing on neuroscience, oncology, hospital and medical device areas for diseases with significant unmet medical need. By allocating significant resources in these treatment areas Otsuka will maintain its commitment to develop and launch products for better patient outcomes.
 

Otsuka America Pharmaceutical, Inc. draws from a number of different sources for our healthcare products in development. The company currently has three general sources for new products:

• Otsuka Pharmaceutical Co., Ltd. (OPC) is one of the largest healthcare companies in Japan. OPC has 44 research institutes worldwide which conduct most of the company's basic research, product development, and toxicology research and development studies. In addition to the OPC research institutes, the Otsuka Pharmaceutical Group owns a number of other businesses engaged in healthcare product development.
   

• Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) is dedicated to research, product development, and clinical development. The professionals at OPDC were invaluable contributors to the development of ABILIFY^® (aripiprazole) Tablets, PLETAL^® (cilostazol) Tablets² and SAMSCA^TM (tolvaptan)³ and are currently pursuing the clinical development of other Otsuka products.
   

• OAPI seeks out products from reputable businesses outside the Otsuka Pharmaceutical Group for development and commercialization.
   

To learn more about clinical trials being conducted by Otsuka, please visit the U.S. National Institute of Health clinical trials registry website, www.clinicaltrials.gov.